ClinicalTrials.gg
CompletedNCT01706315Updated May 9, 2017

This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects

A Phase 1 interventional study of GSK2140944 and Placebo in Infections, Respiratory Tract, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-09.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Respiratory Tract Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Respiratory Tract Infections · GlaxoSmithKline.

Enrollment
5th of 19
72 · median 46
Started
2012
with 2 others
Phase 1
14 of 21
none open now
Registered
8th of 21
by date

Among the 21 studies in Respiratory Tract Infections by GlaxoSmithKline, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2012, is one of 14 in phase 1, and was the 8th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

None of the 21 studies in Respiratory Tract Infections by GlaxoSmithKline is open now. The open studies under Respiratory Tract Infections, anywhere →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Respiratory Tract Infections by GlaxoSmithKline as a file.
02

Study summary

This will be a randomized, placebo-controlled, single blind study to investigate the safety, tolerability and pharmacokinetic (PK) profile of GSK2140944 following repeat oral doses in healthy adult subjects. The study will include a Screening period (40 days), Treatment period (16 days) and a Follow-up period (26 to 30 days). A single dose will be administered on Day 1 for characterization of single dose PK, followed by twice-daily (BID) or thrice-daily (TID) dosing on Days 3 to 16. Subjects may only be randomized to one cohort per the randomization schedule. Up to 6 cohorts will be enrolled using a sequential panel. Subjects in Cohort 1 will receive GSK2140944 (6) and placebo (2). Subsequent cohorts will enroll 16 subjects such that 12 subjects will receive GSK2140944 and 4 subjects will receive placebo, per dose level according to the randomization schedule. Dose escalations are planned to run in successive weeks. Cohort 2 may begin dosing once subjects in Cohort 1 have completed 7 days of BID dosing, PK data is reviewed and safety data from at least 6 subjects is available. Each subsequent dose escalation will commence only when GSK2140944 safety data and available PK data of at least 12 subjects dosed at the previous dose level have been reviewed. The number of cohorts may be reduced or expanded if needed. The first planned dose is 400 milligram (mg) BID but may be modified based upon emergent PK, safety and tolerability data from ongoing clinical study BTZ115198 evaluating single and repeat intravenous (IV) doses of GSK2140944. The projected dose for Cohort 2 is 800 mg BID, Cohort 3 is 1500 mg BID, Cohort 4 is 2300 mg BID or 1500 mg TID and Cohort 5 and cohort 6 will be decided later. The planned maximum dose is 2500 mg TID but may be modified based upon emergent safety, tolerability and PK data. Doses of GSK2140944 or placebo will be administered following a moderate fat meal.

03

Conditions studied

  • Infections, Respiratory Tract
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (AST), alanine aminotransferase (ALT), alkaline phosphatase and \<=1.5x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. - A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GlaxSmithKline (GSK) Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Male or female between 18 and 60 years of age inclusive, at the time of signing the .
  • A female subject is eligible to participate if she is of: Non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea. To confirm post-menopausal status, a blood sample for simultaneous follicle stimulating hormone (FSH) >40 MlU/ml and estradiol \<40 pg/ml (\<147 pmol/L) is confirmatory. Male subjects with female partners of child-bearing potential must agree to use the methods. This criterion must be followed from the time of the first dose of study medication until the final follow-up visit.
  • Body weight >=50 kg and (BMI) within the range 19 to 31 kg/m2 (inclusive).
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion criteria

Exclusion Criteria:

  • A positive pre-study surface antigen or positive antibody result within 3 months of screening or positive (HIV) antibody.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities.
  • Any central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the investigator may place the subject at an unacceptable risk as a participant in this trial or may interfere with the absorption, distribution, metabolism or excretion of drugs.
  • A screening or Day -2 urinalysis positive for protein or glucose (greater than "trace" findings of protein or glucose).
  • A serum creatinine value between screening and Day -2 visit that is increased by more than 0.2 mg/dL (or 15.25 umol/L) changes.
  • History of photosensitivity to quinolones and tendon rupture.
  • Unwillingness to commit to avoid excessive exposure to sunlight which would cause a sunburn reaction from first dose up to and including the follow-up visit.
  • A positive urine test for drugs of abuse or alcohol (or alcohol breath test) at screening or Day -2.
  • History of drug abuse within 6 months of the study
  • History of smoking or use of nicotine containing products within 3 months of screening, or a positive urine cotinine indicative of smoking at screening.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.
  • The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, or use of St. John's Wort within 14 days prior to the first dose of study medication. By exception, the volunteer may take paracetamol or acetaminophen (\<=2 grams/day) up to 48 hours prior to the first dose of study medication. However, the Investigator and GSK study team can review medication on a case by case basis to determine if its use would compromise subject safety or interfere with the study procedures or data interpretation.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinical research unit uses heparin to maintain intravenous cannula patency).
  • Donation of blood in excess of 500 ml within 12 weeks prior to dosing.
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices containing such products from 7 days prior to the first dose of study medication.
  • Screening : Heart rate \<40 and >100 bpm for males and \<50 and >100 bpm for females. PR Interval \<120 and >220 msec, QRS duration \<70 and >100 msec, or QTcF interval >450msec. Evidence of previous myocardial infarction (does not include ST segment changes associated with repolarization); any conduction abnormality (including but not specific to left or right complete bundle branch block, atrioventricular (AV) block [2nd degree or higher], Wolf Parkinson White [WPW] syndrome), sinus pauses >3 seconds, non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular ectopic beats) or any significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety of the individual subject.
  • Screening holter monitoring shows one or more of the following: any symptomatic arrhythmia (except isolated extra systoles); sustained cardiac arrhythmias (such as atrial fibrillation or flutter, supraventricular tachycardia (SVT) [>10 consecutive beats]); sinus tachycardia (or SVT) >150 bpm; non-sustained or sustained ventricular tachycardia (defined as >=3 consecutive ventricular ectopic beats); any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block [2nd degree or higher in an awake subject], WPW syndrome, other pre-excitation syndromes); symptomatic sinus pause or sinus pause >3 seconds - unless patient is straining, vomiting, or having some other type of hypervagal response; 300 or more supraventricular ectopic beats in 24 hours; 250 or more ventricular ectopic beats in 24 hours; Ischemia, diagnosed by a sequence of EKG changes that include flat or down sloping ST-segment depression >0.1 mV, with a gradual onset and offset that lasts for a minimum period of 1 minute. Each episode of ischemia must be separated by a minimum duration of at least 1 minute, during which the ST segment returns back to baseline (1x1x1 rule).
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subject is mentally or legally incapacitated.
  • \<2000 cells per microliter (a single repeat is allowed for eligibility determination).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Cohort 1 - GSK2140944 400 mg

    Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days

    Drug: GSK2140944

  • Placebo comparator
    Cohort 1 - Placebo

    Subjects will be randomized in 6:2 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days

    Drug: Placebo

  • Experimental
    Cohort 2 - GSK2140944 800 mg

    Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 2 will be decided based on the safety and PK data from six subjects in Cohort 1

    Drug: GSK2140944

  • Placebo comparator
    Cohort 2 - Placebo

    Subjects will be randomized in 12:4 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days

    Drug: Placebo

  • Experimental
    Cohort 3 - GSK2140944 1500 mg

    Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 3 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 2

    Drug: GSK2140944

  • Placebo comparator
    Cohort 3 - Placebo

    Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days

    Drug: Placebo

  • Experimental
    Cohort 4 - GSK2140944 2500 mg

    Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 4 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 3

    Drug: GSK2140944

  • Placebo comparator
    Cohort 4 - Placebo

    Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days

    Drug: Placebo

  • Experimental
    Cohort 5 - GSK2140944 TBD

    Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 4

    Drug: GSK2140944

  • Placebo comparator
    Cohort 5 - Placebo

    Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days

    Drug: Placebo

  • Experimental
    Cohort 6 - GSK2140944 TBD

    Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 6 subjects dosed at the Cohort 5

    Drug: GSK2140944

  • Placebo comparator
    Cohort 6 - Placebo

    Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days

    Drug: Placebo

Interventions

  • GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg

  • DrugPlacebo

    Matching placebo will be available

06

What researchers measure

Primary outcomes

  1. GSK2140944 clinical safety data assessed as change from baseline in 12-lead ECG

    12-lead ECGs will be obtained at each timepoint using an ECG machine, after the subject has rested in a semi-supine position for at least 10 minutes

    Time frame: Day 1, Day 4, Day 7, Day 10, Day 13, Day 16, Day 18 and at the Follow-up visit

  2. GSK2140944 clinical safety data from dual-lead cardiac monitoring

    Continuous dual-lead cardiac monitoring will be obtained at each timepoints using an ECG machine

    Time frame: Day 1

  3. GSK2140944 clinical safety data assessed as change from baseline in clinical laboratory tests

    Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters

    Time frame: Day -2 and pre-morning dose on Day 2, Day 5, Day 8, Day 11, and Day 14; on the morning of Day 17 and at the Follow-up visit

  4. GSK2140944 clinical safety data assessed as by number of adverse events (AE)

    Safety and tolerability parameters will include recording of AEs, throughout the study

    Time frame: Up to the Follow-up visit

  5. GSK2140944 clinical safety data assessed as change from baseline in blood pressure

    Vital sign measurements will be done in semi-supine position and will include systolic and diastolic blood pressure

    Time frame: Day -1, Day 1, Day 4, Day 7, Day 10, Day 13, Day 16, Day 18 and the Follow-up visit

  6. GSK2140944 clinical safety data assessed as change from baseline in heart rate

    Vital sign measurements will be done in semi-supine position and will include pulse rate

    Time frame: Day -1, Day 1, Day 4, Day 7, Day 10, Day 13, Day 16, Day 18 and the Follow-up visit

  7. Pharmacokinetic parameter: AUC(0-12) following single dose of GSK2140944

    Pharmacokinetic data will include area under the curve from time zero (pre-dose) to 12 hour post-dose (AUC(0-12)) following single dose of GSK2140944

    Time frame: Day 1

  8. Pharmacokinetic parameter: AUC(0-24) following single dose of GSK2140944

    Pharmacokinetic data will include area under the curve from time zero (pre-dose) to 24 hour post-dose (AUC(0-24)) following single dose of GSK2140944

    Time frame: Up to Day 2

  9. Pharmacokinetic parameter: AUC(0-t) following single dose of GSK2140944

    Pharmacokinetic data will include area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC(0-t)) following single dose of GSK2140944

    Time frame: Up to Day 3

  10. Pharmacokinetic parameter: AUC(0-infinity) following single dose of GSK2140944

    Pharmacokinetic data will include area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)) following single dose of GSK2140944

    Time frame: Up to Day 3

  11. Pharmacokinetic parameter: Cmax following single dose of GSK2140944

    Pharmacokinetic data will include maximum observed concentration (Cmax) following single dose of GSK2140944

    Time frame: Up to Day 3

  12. Pharmacokinetic parameter: tmax following single dose of GSK2140944

    Pharmacokinetic data will include time of occurrence of Cmax (tmax) following single dose of GSK2140944

    Time frame: Up to Day 3

  13. Pharmacokinetic parameter: t1/2 following single dose of GSK2140944

    Pharmacokinetic data will include terminal phase half-life (t1/2) following single dose of GSK2140944

    Time frame: Up to Day 3

  14. Pharmacokinetic parameter: AUC(0-tau) following repeat dose of GSK2140944

    Pharmacokinetic data will include area under the concentration-time curve over the dosing interval (AUC(0-tau)) following repeat dose of GSK2140944

    Time frame: Day 14, Day 15 and Day 16

  15. Pharmacokinetic parameter: Cmax following repeat dose of GSK2140944

    Pharmacokinetic data will include Cmax following repeat dose of GSK2140944

    Time frame: Day 14, Day 15 and Day 16

  16. Pharmacokinetic parameter: tmax following repeat dose of GSK2140944

    Pharmacokinetic data will include tmax following repeat dose of GSK2140944

    Time frame: Day 14, Day 15 and Day 16

  17. Pharmacokinetic parameter: Ctau following repeat dose of GSK2140944

    Pharmacokinetic data will include pre-dose (trough) concentration at the end of the dosing interval (Ctau) following repeat dose of GSK2140944

    Time frame: Day 14, Day 15 and Day 16

  18. Pharmacokinetic parameter: Ro following repeat dose of GSK2140944

    Pharmacokinetic data will include accumulation ratio (Ro) following repeat dose of GSK2140944

    Time frame: Day 14, Day 15 and Day 16

  19. Pharmacokinetic parameter: AUC(0-8) following single dose of GSK2140944

    Pharmacokinetic data will include area under the curve from time zero (pre-dose) to 8 hour post-dose (AUC\[0-8\]) following single dose of GSK2140944

    Time frame: Day 1

Secondary outcomes

  1. To assess preliminary dose proportionality using PK parameter AUC(0-infinity) following single dose of GSK2140944

    Preliminary dose proportionality will be assessed using PK parameter (AUC(0-infinity)) following single dose of GSK2140944

    Time frame: Up to Day 3

  2. To assess preliminary dose proportionality using PK parameter Cmax following single dose of GSK2140944

    Preliminary dose proportionality will be assessed using PK parameter Cmax following single dose of GSK2140944

    Time frame: Up to Day 3

  3. To assess preliminary dose proportionality using PK parameter AUC(0-tau) following repeat doses of GSK2140944

    Preliminary dose proportionality will be assessed using PK parameter (AUC(0-tau) following repeat doses of GSK2140944

    Time frame: Day 14, Day 15 and Day 16

  4. To assess preliminary dose proportionality using PK parameter Cmax following repeat doses of GSK2140944

    Preliminary dose proportionality will be assessed using PK parameter Cmax following repeat doses of GSK2140944

    Time frame: Day 14, Day 15 and Day 16

  5. To examine extent of accumulation using PK parameter Ro using AUC(0-tau) following repeat doses of GSK2140944

    Accumulation ratio will be assessed using PK parameter AUC(0-tau) following repeat doses of GSK2140944

    Time frame: Day 14, Day 15 and Day 16

  6. To examine extent of accumulation using PK parameter AUC(0-tau) following single dose of GSK2140944

    Accumulation ratio will be assessed using PK parameter AUC(0-tau) following single dose of GSK2140944

    Time frame: Day 1

  7. To examine the extent of time invariance using repeat dose AUC(0-tau)

    The extent of time invariance will be assessed using PK parameter AUC(0-tau) following repeat dose

    Time frame: Day 14, Day 15 and Day 16

  8. To examine the extent of time invariance using single dose AUC(0-infinity)

    The extent of time invariance will be assessed using PK parameter AUC(0-infinity) following single dose

    Time frame: Up to Day 3

  9. To assess achievement of steady-state following repeat oral doses of GSK2140944

    Achievement of steady-state will be assessed using trough concentrations at the end of the dosing interval (Ctau) collected at pre-morning dose on Days 14 and 15 (together with pre-morning dose Ctau on Days 16 from the full PK profiles on Day 16).

    Time frame: Day 14, Day 15 and Day 16

07

Study locations

1 site
  • GSK Investigational Site
    Overland Park, Kansas 66211, United States
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Dec 2013, 13 months.

Of 26 industry-sponsored phase 1 interventional studies under Respiratory Tract Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 13 months is above that.

Counting every sponsor, half of 35 studies reached it within 8 months; a quarter within 1 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2012
First posted
Oct 15, 2012
StartActual
Oct 17, 2012
Primary completionActual
Dec 13, 2013
CompletionActual
Dec 13, 2013
Last update
May 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01706315
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 15, 2012
Start date
Oct 17, 2012
Primary completion
Dec 13, 2013
Completion
Dec 13, 2013
Last update
May 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion